Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as a 30 mg tablet for oral use. It is used to prevent cerebral vasospasm after subarachnoid hemorrhage and to treat other cerebrovascular disorders in adult patients.

GNH USA supplies Nimotop as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimodipine is indicated for conditions involving the cerebral vasculature where vasospasm or reduced blood flow is a concern.

- Prevention of cerebral vasospasm after subarachnoid hemorrhage: reduces the risk of delayed ischemic neurological deficits. - Treatment of cerebral vasospasm: promotes cerebral blood flow to mitigate ischemia. - Management of other cerebrovascular disorders: improves cerebral perfusion in selected adult patients.

Adverse reactions may occur with nimodipine therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness. - Dizziness: often related to blood pressure changes. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Hypotension: significant drop in blood pressure requiring medical attention. - Bradycardia: unusually slow heart rate. - Allergic reactions: rash, angioedema, or anaphylaxis in rare cases.

When prescribing nimodipine, several safety considerations are important.

- Pregnancy: Category B; use only if the potential benefit justifies the potential risk. - Breastfeeding: Caution; monitor the infant for any adverse effects. - Renal impairment: Adjust dosing if renal function is markedly reduced. - Hepatic impairment: Use with caution; liver disease may affect drug metabolism. - Concomitant antihypertensives: Monitor blood pressure closely to avoid excessive hypotension. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Nimodipine may interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations of nimodipine. - Other potent vasodilators (e.g., nitroglycerin): risk of severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - NSAIDs: may blunt the antihypertensive effect of nimodipine. - Beta‑blockers: additive effects on heart rate and blood pressure.